Insider · CIK 0001539215
Padmanabh P. Bhatt
Files at SUPN (SUPERNUS PHARMACEUTICALS, INC.). First filing Dec 4, 2024, latest Mar 18, 2026.
In brief
Padmanabh P. Bhatt files SEC Form 4 as officer at SUPN (SUPERNUS PHARMACEUTICALS, INC.). Since Dec 4, 2024, Padmanabh P. Bhatt has reported 0 open-market buys worth $0 and 5 open-market sells worth $6.7M, the latest filed on Mar 18, 2026.
A track record needs three past buys with six months of prices behind them; Padmanabh P. Bhatt has 0, so none is measured yet.
The newest scored trade: sold $5.4M of SUPN on Mar 16, 2026, filed Mar 18, 2026, scored 40 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $5.4M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SUPN: SUPERNUS PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | SUPERNUS PHARMACEUTICALS, INC. | $5.4M 107,250 shares | -160% | +66% from low-12% from high | |
| 13Weak | SUPERNUS PHARMACEUTICALS, INC. | $32k 710 shares | -5% | +63% from low-14% from high | |
| 6Weak | SUPERNUS PHARMACEUTICALS, INC. | $376k 9,477 shares | -48% | - | |
| 1Weak | SUPERNUS PHARMACEUTICALS, INC. | $130k 3,273 shares | -26% | - | |
| 22Weak | SUPERNUS PHARMACEUTICALS, INC. | $788k 21,495 shares | -117% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 17, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 57,250 0.10% of outstanding | $2.9M | Mar 17, 2026 | $2.5M |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 50,000 0.00% of outstanding | $2.5M | Mar 16, 2026 | none |
| Jan 27, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 22,000 0.04% of outstanding | $848k | Jan 27, 2025 | $788k |
| Dec 3, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 21,495 0.04% of outstanding | $802k | Dec 3, 2024 | none |
Transactions
The newest 50 of 78 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +2,500 | $0.00 | $0 | 19,795 | Aug 14, 2026 |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -1,158 | $46.57 | $54k | 18,637 | Aug 14, 2026 |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -2,500 | $0.00 | $0 | 0 | Aug 14, 2026 |
| Jul 29, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +2,500 | $0.00 | $0 | 2,500 | Jul 31, 2026 |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +22,750 | $36.75 | $836k | 39,794 | Mar 18, 2026 |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +4,250 | $29.61 | $126k | 44,044 | Mar 18, 2026 |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +18,000 | $32.20 | $580k | 62,044 | Mar 18, 2026 |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +5,000 | $27.94 | $140k | 67,044 | Mar 18, 2026 |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -34,114 | $50.18 | $1.7M | 32,930 | Mar 18, 2026 |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -15,886 | $50.49 | $802k | 17,044 | Mar 18, 2026 |
| Mar 17, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +22,750 | $39.40 | $896k | 39,794 | Mar 18, 2026 |
| Mar 17, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +12,250 | $36.75 | $450k | 52,044 | Mar 18, 2026 |
| Mar 17, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +15,000 | $38.60 | $579k | 67,044 | Mar 18, 2026 |
| Mar 17, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -27,710 | $49.95 | $1.4M | 39,334 | Mar 18, 2026 |
| Mar 17, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -22,290 | $50.73 | $1.1M | 17,044 | Mar 18, 2026 |
| Mar 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +7,250 | $39.40 | $286k | 24,294 | Mar 18, 2026 |
| Mar 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -6,838 | $49.55 | $339k | 17,456 | Mar 18, 2026 |
| Mar 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -412 | $50.48 | $21k | 17,044 | Mar 18, 2026 |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -22,750 | $0.00 | $0 | 12,250 | Mar 18, 2026 |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -4,250 | $0.00 | $0 | 0 | Mar 18, 2026 |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -18,000 | $0.00 | $0 | 0 | Mar 18, 2026 |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 15,000 | Mar 18, 2026 |
| Mar 17, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -22,750 | $0.00 | $0 | 7,250 | Mar 18, 2026 |
| Mar 17, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -12,250 | $0.00 | $0 | 0 | Mar 18, 2026 |
| Mar 17, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 5,000 | Mar 18, 2026 |
| Mar 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -7,250 | $0.00 | $0 | 0 | Mar 18, 2026 |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +1,250 | $0.00 | $0 | 17,694 | Feb 26, 2026 |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -650 | $50.69 | $33k | 17,044 | Feb 26, 2026 |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -1,250 | $0.00 | $0 | 1,250 | Feb 26, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +1,125 | $0.00 | $0 | 16,025 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -581 | $51.35 | $30k | 15,444 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +750 | $0.00 | $0 | 16,194 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -354 | $50.86 | $18k | 15,840 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +1,250 | $0.00 | $0 | 17,090 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -646 | $50.86 | $33k | 16,444 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -1,125 | $0.00 | $0 | 3,375 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -750 | $0.00 | $0 | 0 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -1,250 | $0.00 | $0 | 2,500 | Feb 25, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Employee Stock Option (Right to Buy)derivative | +13,500 | $0.00 | $0 | 13,500 | Feb 20, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +3,000 | $0.00 | $0 | 3,000 | Feb 20, 2026 |
| Dec 18, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +1,500 | $0.00 | $0 | 15,218 | Dec 19, 2025 |
| Dec 18, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock | -710 | $44.44 | $32k | 14,508 | Dec 19, 2025 |
| Dec 18, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -1,500 | $0.00 | $0 | 0 | Dec 19, 2025 |
| Nov 13, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +1,500 | $0.00 | $0 | 1,500 | Nov 17, 2025 |
| Aug 25, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +1,250 | $0.00 | $0 | 14,299 | Aug 27, 2025 |
| Aug 25, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -581 | $41.46 | $24k | 13,718 | Aug 27, 2025 |
| Aug 25, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -1,250 | $0.00 | $0 | 0 | Aug 27, 2025 |
| Aug 7, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +1,250 | $0.00 | $0 | 1,250 | Aug 8, 2025 |
| Mar 5, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -335 | $33.05 | $11k | 13,854 | Mar 5, 2025 |
| Mar 5, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -575 | $33.05 | $19k | 13,279 | Mar 5, 2025 |
Questions about Padmanabh P. Bhatt
Answered from the filings on this page, as of the latest one.
Is Padmanabh P. Bhatt buying or selling?
In the last 12 months Padmanabh P. Bhatt reported 0 open-market buys worth $0 and 2 open-market sells worth $5.4M on SEC Form 4; the latest was sold $5.4M of SUPN on Mar 16, 2026. Grants, option exercises and tax withholding are not counted.
How did Padmanabh P. Bhatt's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Padmanabh P. Bhatt has 0.
Where does Padmanabh P. Bhatt file Form 4?
Padmanabh P. Bhatt has filed Form 4 at SUPN (SUPERNUS PHARMACEUTICALS, INC.) as Sr. VP of IP, CSO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.